Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 7:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–2 of 2 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Acute Non-cardioembolic Ischemic Stroke Clear all

Completed Phase 3 Interventional

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

NCT05686070

View directory record Official record

Conditions: Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke, High-risk Transient Ischemic Attack
Interventions: Asundexian (BAY2433334), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older

Enrollment: 12,327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 108
States / cities: Fairhope, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more

Source: ClinicalTrials.gov public record

Updated Nov 11, 2025 · Synced May 21, 2026, 7:49 PM EDT

Completed Phase 2 Interventional Results available

Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.

NCT04304508

View directory record Official record

Conditions: Acute Non-cardioembolic Ischemic Stroke
Interventions: BAY2433334, BAY2433334 matching placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 45 Years and older

Enrollment: 1,808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Tampa, Florida • Golden Valley, Minnesota • Kansas City, Missouri + 2 more

Source: ClinicalTrials.gov public record

Updated Apr 18, 2023 · Synced May 21, 2026, 7:49 PM EDT